Home › SYNDAX AND MERCK ANNOUNCE FIRST PATIENTS DOSED IN PHASE 1b/2 CLINICAL TRIAL OF ENTINOSTAT AND KEYTRUDA
 

Keywords :   


SYNDAX AND MERCK ANNOUNCE FIRST PATIENTS DOSED IN PHASE 1b/2 CLINICAL TRIAL OF ENTINOSTAT AND KEYTRUDA

2015-09-28 14:00:56| Merck.com - Product News

Dateline City: WALTHAM, Mass. and KENILWORTH, N.J. Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma WALTHAM, Mass. and KENILWORTH, N.J. Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndaxs entinostat in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma. Language: English read more

Tags: of trial phase patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
27.04Commentary: Committed to End Plastic Waste
26.04Dead whistleblower accused Boeing of safety breaches
26.04Introducing Mens Hybrid Skincare Brand Enhanse
26.04Washington Corner April 2024
26.04Does history repeat itself?
26.04FDA finalizes guidance to provide further clarity on Veterinary Feed Directives
26.04Post Office paid widow in instalments for silence
26.04NCBA statement on USDA final traceability rule
More »